HealthMore in Health→
Phase 1 trial suggests cevostamab could widen options in heavily pretreated multiple myeloma
Key Takeaways
- A phase 1 trial tested cevostamab in 324 patients with relapsed or refractory multiple myeloma.
- Most participants had heavily pretreated disease, and nearly half had prior BCMA-targeted therapy.
- The drug produced a 42.1% objective response rate and a median response duration of 11.2 months.
- The maximum tolerated dose was not reached, though serious adverse events were common.
DE
DT Editorial Team··via nature.com
